Igniting a systemic immune response to cancer
Replimune is a clinical-stage biotech company focused on revolutionizing cancer treatment with a new class of oncolytic immunotherapies intended to activate a powerful and durable full-body anti-tumor response.
Now approved: TUDRIQEV
A new option for patients with advanced melanoma.
Our Mission
We imagine a world where cancer is a curable disease. Replimune's mission is to revolutionize cancer treatment through comprehensive activation of a tumor-specific immune response — potentially treating a broad range of cancer types.
New hope for advanced melanoma patients
Our first therapy, TUDRIQEV, is an oncolytic immunotherapy administered in combination with nivolumab for patients with advanced melanoma that have progressed on an anti-PD‑1 containing regimen.
Creating a systemic and durable immune response to cancer
Replimune is pioneering a novel class of oncolytic immunotherapies intended to kill the tumor locally, alter the tumor microenvironment, and ignite a powerful anti-tumor immune response.
Investigating new treatments for cancer
Our clinical programs are designed to evaluate the safety and effectiveness of our investigational therapies in a range of solid tumors as single agents and combination with other immunotherapies. Clinical trials give access to new therapies and help us develop treatments that will deliver better outcomes than the existing standard of care.